The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
have a look at Cizzle Biotech, they do a blood test for lung cancer, I bought 100k @1.73p and they are now at just over 4p
What a disaster for the shareholders. Company looking to move home and list in Kazakhstan!! Vlad and western sanctions have screwed a once great company.
This a dead cert short, only if you can find a broker who will let you!!
I haven't yet Bojo, enjoying the Russian roulette buzz with O&G stocks at the moment :) Met AN over a decade or so ago when I was still in Academia (I retired very young from it ) as the whole Parsortix story was unfolding. I kept up with it for ` year or two and with all the delays, it fell off my radadr till you mentioned it back in 2020. AN is a smart guy, they sold something to ARM to plough all efforts into Parsortix, so his pedigree is not in doubt.
I have my concerns around the barriers to adoption and the high burn rate. I need to find some time and do the research on it throughly to convince myself of the investment case. The usefulness of the technology is not in doubt, but more so whether the NHS/Industry are ready to adopt it, and how far are we from it. Personalised medicine is a buzz word that gets banded about, but it requires a lot of infrastructure investment from IT connected to wide availability of sequencing technology.
What do you think of Angle MJ? Did you buy in yet.
There is always a sting in the tail with Avacta and it has large mcap already.
Avacta flying atm. Great update. Another one I am not invested in. Looks way over priced considering there has not been any tumor response. Or, did I miss that RNS?
Telegram MJ
Search Parsortix Angle for Angle group. Also a link on twitter
ODTT crew for all the old posters like Maf, John etc
what other group Bojo?
so what's on the radar folks?
I can suggest OBI - John mentioned this on COPL board. Looks like an interesting play for mitigitating hospital acquired infections as well as other settings, went through the presentation and the Q&A earlier. They are starting P3 and then fast track to FDA approval. No position here yet, need to do more research.
Cizzle - Lung cancer test, Chinese partner testing it etc... small position here.
Mostly spending time on O&G these days.
Angle funds include:
So over 20% of Angle now owned by US investors, Fidelity, MS, Conifer and now Global Frontier. Apart from BG, all UK fund managers sitting it out.
From another poster
Looks like the US funds are placing a lot of money in Europe at the moment …
Even the dog shares are well up in 2023 so far which means a lot of money is being invested in the whole sector as very undervalued since 2022
angle?well higher,since you mentioned it bojo
hemo?...whopper volumes,sinceaweek ago
Love Farn ,
Slow burner but loads of potential for partnering with BIG pharma …
More great news as they have a second responder! My question is, does Scancell? Clear differences between the two vaccines but it appears SCLP either have a super responder to Moditope or maybe more to its pan cancer vaccine. Soon find out in it's basket trial with update due...
Nolu,
Looking at Hemo. It seems to have a higher volume than IQAI. Both seen impressive and sustained rises against the tide so to speak. Hope you are still in both?
The other group is till going strong. Maf, John, Wilbo, XV, and the others have have asked me to reiterate that your views would be valid and welcome over there. Door is always open! That applies to you Troajan too.
I do a bit of both which works out well for me.
ATB.
Moving up, but still a long long long way to target
Maybe at 1.8. There are so many to choose from!
Have a look at IQAI …
Cheap as chips
Anything between 37 and 40 vintage would be a good!
Don’t know how long I will be onboard .. it depends on what champagne is being served :-)
Haha! Welcome aboard!
I am not as pessimistic as you :-)
Traders have this for now. Lets see if they last the day...I guess they will be back tomorrow.
Private investors jumping in on a 6% rise is just gonna burn their cash. I think 20p or there about's by Friday. If it bounces then I'll buy Scancell which is about to fly IMO.
Bojo2022,
The wind has turned and we should see a technical rebound at the very least
Wait and see
about Angle? What is a good entry point? Looks like 20p by Friday imo sad to say. If the selling does not slow then maybe less!
We have received feedback on Telegram that the tone is due to NOMAD (heavy hint). No doubt the initial heavy drop triggered institutional sells.